What Is Semax?
Semax is a synthetic peptide with the sequence:
Met-Glu-His-Phe-Pro-Gly-Pro.
It is often described as ACTH(4-7)-PGP because its structure combines the ACTH(4-7) fragment with a Pro-Gly-Pro tail.
The ACTH fragment retains neuroregulatory activity without reproducing the full hormonal effects associated with intact ACTH.
The PGP portion was added to improve resistance to enzymatic breakdown and extend biological activity.
This makes Semax a good example of peptide engineering:
start with a biologically active natural fragment, then modify it to make the signal more stable and useful for research.
Why Are Researchers Interested in It?
Semax has attracted attention because its research spans several areas of neuroscience at once.
These include:
neuroprotection, ischemic injury, stroke rehabilitation, BDNF, NGF, neuroplasticity, cognition, memory, attention, dopamine signaling, inflammation, and oxidative stress.
Unlike many experimental neuropeptides, Semax also has human clinical research behind it.
Much of that work originated in Russia, where Semax has been studied in neurological and cerebrovascular conditions.
That gives it a stronger translational history than compounds supported only by animal or cell experiments.
How Does Semax Work?
Semax does not appear to work through one simple receptor.
Instead, its effects seem to involve several signaling systems.
Research has connected Semax with:
BDNF signaling, NGF signaling, Trk receptors, dopamine regulation, inflammatory pathways, gene expression, antioxidant responses, and neurotrophic signaling.
This broader pattern suggests Semax acts more like a neuroregulatory peptide than a conventional single-target drug.
That may help explain why its research covers both acute neurological injury and cognitive function.
BDNF & Neuroplasticity
BDNF stands for brain-derived neurotrophic factor.
It is one of the most important proteins involved in:
neuronal survival, synaptic plasticity, learning, memory, and recovery after neurological injury.
Semax research has repeatedly focused on BDNF.
Animal studies have shown that Semax can increase transcription of BDNF and related neurotrophin receptors after cerebral ischemia.
One study found increased expression of Bdnf, TrkA, TrkB-related pathways, NGF, and other neurotrophic signals following experimental ischemia.
This is one of the strongest mechanistic reasons Semax remains interesting.
Rather than simply changing alertness temporarily, it may influence pathways involved in how the nervous system adapts and repairs itself.
Stroke Research
Stroke is one of Semax’s most important research areas.
Early clinical research examined Semax in patients during the acute phase of ischemic stroke.
A 1997 clinical study evaluated 30 patients receiving Semax compared with 80 conventionally treated controls and reported improvements in neurological recovery measures.
Later studies continued investigating Semax during stroke rehabilitation.
A study involving 110 patients examined Semax alongside rehabilitation after ischemic stroke and found higher plasma BDNF levels and better improvement in Barthel Index outcomes among Semax-treated groups.
These studies are not equivalent to the large multinational trials usually required for modern U.S. drug approval.
But they do establish that Semax has been studied clinically in actual neurological disease rather than only in laboratory models.
Neuroprotection
Neuroprotection refers to strategies that help protect nervous tissue from damage.
Semax has demonstrated neuroprotective effects across experimental ischemia models.
Research has connected these effects with:
neurotrophic signaling, inflammatory regulation, cerebral blood-flow-related processes, oxidative stress, and cellular survival pathways.
Clinical research in acute ischemic stroke also reported changes in inflammatory signaling consistent with potential neuroprotective effects.
This makes Semax especially interesting in situations where neurons are under acute metabolic stress.
Inflammation & Ischemic Injury
Brain ischemia triggers much more than simple oxygen deprivation.
After blood flow is disrupted, damaged tissue can develop:
oxidative stress, excitotoxicity, inflammation, mitochondrial dysfunction, and secondary cellular injury.
Semax research suggests the peptide may influence some of these downstream responses.
One clinical investigation reported shifts in post-ischemic inflammatory mediators during Semax treatment.
That creates an important distinction.
The goal of neuroprotection is not merely to restore blood flow.
Researchers also want to reduce the chain reaction of damage that can continue afterward.
NGF & Other Neurotrophins
BDNF is not the only neurotrophic factor associated with Semax.
Experimental studies have also reported effects involving:
NGF, NT-3, TrkA, TrkB, and TrkC.
These molecules help regulate neuronal survival, growth, differentiation, and synaptic function.
Semax and its PGP fragment have been shown to alter transcription of several neurotrophin and receptor genes following experimental cerebral ischemia.
This broad neurotrophic activity helps explain why Semax research extends into both injury recovery and cognition.
Cognition & Memory
Semax has also been studied as a nootropic peptide.
Experimental research has explored:
learning, memory formation, attention, cognitive performance, and information processing.
A published review discussing Semax in neurodevelopmental research noted reported effects on memory and attention in both rodents and humans after intranasal administration.
These findings are one reason Semax is frequently discussed in cognitive-enhancement communities.
However, clinical evidence for improving cognition in healthy people is less developed than its neurological research.
The most scientifically grounded interpretation is that Semax may influence neuroplasticity and cognitive signaling, with the strongest clinical relevance historically centered on neurological dysfunction rather than general enhancement.
Attention Research
Attention is closely tied to several neurotransmitter systems, particularly dopamine.
Semax has been studied in relation to attention and dopamine signaling.
Researchers have proposed that its effects on dopamine and BDNF pathways could make it relevant to attention-related disorders, although such uses remain experimental.
This research is especially interesting because BDNF and dopamine are both involved in neural adaptation and attentional control.
Semax therefore provides a potential bridge between neurotrophic and neurotransmitter mechanisms.
Dopamine Research
Dopamine plays important roles in:
motivation, attention, reward, movement, learning, and working memory.
Experimental Semax research suggests it can influence dopaminergic signaling.
Unlike conventional stimulants, Semax is not primarily understood as a direct dopamine-releasing drug.
Instead, it appears to alter regulatory systems surrounding dopamine signaling.
That distinction may explain why researchers have explored Semax as a cognitive and neuroprotective compound rather than simply as a stimulant.
Semax & ACTH
Semax originates from ACTH biology, but it should not be treated as equivalent to ACTH.
ACTH is a much larger peptide hormone produced by the pituitary gland.
Its major endocrine role involves stimulating the adrenal glands to produce cortisol.
Semax contains only a short ACTH-derived fragment.
It was specifically developed to preserve certain neurological properties while avoiding the full adrenal-stimulating hormonal activity of intact ACTH.
This is why Semax is usually classified as a neuropeptide rather than a corticosteroid-regulating hormone.
Why Add Pro-Gly-Pro?
The Pro-Gly-Pro sequence is an important part of Semax’s design.
Short peptides can be degraded rapidly by enzymes.
Adding PGP appears to improve stability and may also contribute biological activity of its own.
Research comparing Semax and PGP has found partially overlapping effects on neurotrophin gene expression after cerebral ischemia.
This suggests PGP is not necessarily just an inert stabilizing tail.
It may participate in some of Semax’s broader biological effects.
Intranasal Research
Semax has commonly been studied through intranasal administration.
This route is particularly interesting for neuropeptides because the nasal cavity may provide access to systemic circulation and pathways relevant to the central nervous system.
Orally administered peptides can be rapidly degraded in the gastrointestinal tract.
Intranasal delivery offers a way to avoid much of that digestive breakdown.
Semax therefore became one of the more established examples of a neuropeptide studied through nasal administration.
Nose-to-Brain Delivery
Researchers are increasingly interested in nose-to-brain drug delivery.
The nasal cavity has anatomical connections involving the olfactory and trigeminal pathways.
Certain molecules may potentially reach central nervous-system structures through these routes.
This does not mean every nasal peptide goes directly into the brain.
Absorption varies substantially depending on molecular structure, formulation, dose, and nasal physiology.
Still, Semax’s long history of intranasal research has made it particularly relevant to this field.
Semax vs. Selank
Semax and Selank are frequently discussed together.
Both are synthetic neuropeptides originating from Russian research programs.
Their research areas overlap, but their emphasis differs.
Selank is more strongly associated with:
anxiety, stress resilience, emotional regulation, GABAergic signaling, and neuroimmune effects.
Semax is more strongly associated with:
neuroprotection, cognition, BDNF, learning, memory, stroke, and neurological recovery.
A simplified way to think about them is:
Selank leans toward stress regulation.
Semax leans toward neuroplasticity and neuroprotection.
Both compounds reach beyond those categories.
Semax vs. Adamax
Adamax is a modified derivative associated with the Semax family.
The goal behind Adamax-style modifications is generally to alter properties such as stability, lipophilicity, or duration.
However, direct peer-reviewed evidence for Adamax is far thinner than for Semax.
Semax itself has animal research, mechanistic studies, and published human clinical work.
So while Adamax may represent an interesting next-generation analogue, Semax currently has the stronger scientific foundation.
Semax vs. N-Acetyl Semax Amidate
Modified Semax analogues such as N-Acetyl Semax Amidate are designed using peptide-engineering strategies intended to potentially improve stability.
N-terminal acetylation and C-terminal amidation can sometimes reduce enzymatic degradation.
But structural modification creates a new molecule.
The substantial research history of Semax cannot automatically be transferred to modified analogues.
That distinction is particularly important when evaluating commercial research products.
Cerebrovascular Research
Semax has also been studied in chronic cerebrovascular insufficiency.
One published study reported clinical improvement and stabilization in patients with cerebrovascular disease following Semax treatment.
Again, the methodological standards and scale of much of this literature differ from large modern FDA registration trials.
Still, the existence of human cerebrovascular research makes Semax unusual among experimental peptides frequently discussed online.
Evidence Snapshot
Natural biological origin: Semax is synthetic but derived from the biologically active ACTH(4-7) fragment.
Neuroprotective evidence: Strong preclinical foundation with human clinical research, especially in ischemic stroke.
Stroke research: Meaningful human evidence from Russian clinical studies.
BDNF and neurotrophin research: Strong mechanistic evidence.
Cognition and attention: Promising experimental and limited human evidence.
Dopamine signaling: Meaningful mechanistic research.
Inflammation and ischemic injury: Promising experimental and clinical findings.
U.S. regulatory status: Not FDA approved.
What Do We Know?
Semax has a deeper research history than many compounds commonly described as nootropic peptides.
We know it can influence:
BDNF, neurotrophic signaling, gene expression, inflammatory responses, cognition-related pathways, and recovery processes following cerebral ischemia.
Human stroke and rehabilitation studies have reported measurable clinical and biological effects.
This means Semax is not simply an internet-era “brain peptide.”
It emerged from decades of neurological peptide research.
What Are Researchers Still Trying to Determine?
The biggest need is for larger, independent, internationally conducted clinical trials.
Researchers still need clearer answers about:
pharmacokinetics, dose-response relationships, long-term safety, healthy-person cognitive effects, optimal neurological indications, formulation differences, and which molecular pathways are most responsible for its effects.
Another important issue is product identity.
The FDA has noted that multiple salts, derivatives, and differently characterized substances can be marketed under the general name “Semax.”
That makes precise chemical identification particularly important when interpreting research or evaluating products.
Research & Regulatory Status
Semax is not an FDA-approved drug in the United States.
In 2026, the FDA reviewed Semax and Semax acetate as substances nominated for potential use in traditional compounding.
The agency stated that neither Semax nor Semax acetate is a component of an FDA-approved drug and that there is no applicable USP or NF drug-substance monograph for them.
FDA reviewers also raised concerns about inconsistent naming and characterization among substances marketed as Semax.
That regulatory issue is separate from the scientific literature.
Semax has genuine research behind it, but research evidence for a molecule does not guarantee the identity or quality of an unapproved commercial product.
Your Pep Resource Takeaway
Semax is one of the most compelling neuropeptides in the library because its research connects brain protection, neuroplasticity, BDNF, cognition, and neurological recovery.
Its development from the ACTH(4-7) fragment demonstrates how researchers can isolate a biologically interesting section of a natural hormone and engineer it into something with very different pharmacological goals.
The strongest evidence centers on neuroprotection and cerebrovascular research, including human studies involving ischemic stroke and rehabilitation.
Its effects on BDNF and other neurotrophic pathways provide an especially interesting mechanism for understanding why researchers continue investigating Semax in cognition and recovery.
The evidence base is not perfect.
Much of the clinical research originates from Russia, and Semax has not undergone the large international development program needed for FDA approval.
But compared with many experimental nootropic peptides, Semax has a substantial and unusually deep scientific history.
For researchers interested in BDNF, neuroplasticity, stroke recovery, cognition, memory, attention, dopamine, neuroprotection, and brain injury, Semax remains one of the most noteworthy peptides in neuropeptide research.
Research Areas / Search Keywords
Semax, Semax peptide, ACTH 4-7 PGP, ACTH(4-7)-PGP, Met-Glu-His-Phe-Pro-Gly-Pro, MEHFPGP, neuropeptide, nootropic peptide, brain peptide, cognitive peptide, cognition research, memory research, learning research, focus research, attention research, brain fog research, neuroprotection, neuroprotective peptide, stroke research, ischemic stroke, cerebral ischemia, stroke recovery, stroke rehabilitation, cerebrovascular research, cerebral blood flow research, brain injury research, neurological recovery, BDNF, brain-derived neurotrophic factor, NGF, nerve growth factor, neurotrophins, TrkA, TrkB, TrkC, neuroplasticity, synaptic plasticity, neuronal survival, dopamine research, dopamine signaling, motivation research, attention peptide, oxidative stress, brain inflammation, neuroinflammation, inflammatory signaling, ischemia reperfusion, PGP peptide, Pro-Gly-Pro, intranasal Semax, nasal peptide, nose-to-brain delivery, Russian peptide, Selank vs Semax, Semax vs Selank, Adamax, Semax vs Adamax, N-Acetyl Semax Amidate, modified Semax, ACTH fragment, research peptide, experimental peptide, peptide science.
Educational Disclaimer
This profile is provided for educational and research-information purposes only. Published research involving ischemic stroke, cognition, BDNF, neuroprotection, or neurological recovery does not establish Semax as an FDA-approved treatment in the United States. Much of the human clinical literature originates from Russian research programs, and modern large-scale independent trials remain limited. Unapproved products marketed as Semax should not be assumed to match the identity, purity, formulation, or performance of material used in published research.